Investor centre

Company highlights

• Mature pipeline with two phase III drugs
• ASA404: partnered with Novartis
  – with blockbuster potential in lung cancer
  – also to be developed in breast cancer
  – US co-marketing option with Novartis
  – target 2011 filing for lung cancer
• AS1413: potential first product registration for secondary AML
• AS1411: first aptamer in oncology, with broad potential
• Flt3 program: attractive divestible asset in auto-immune diseases
• Strong cash position to support all priority programs